Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

International Journal of Cancer

Volumn 137, Issue 10, 2015, Pages 2513-2519

  Sefrioui, David ^a,b   Perdrix, Anne ^b,c   Sarafan Vasseur, Nasrin ^a,b   Dolfus, Claire ^b   Dujon, Antoine ^d   Picquenot, Jean Michel ^c   Delacour, Julien ^a,b   Cornic, Marie ^c   Bohers, Elodie ^c   Leheurteur, Marianne ^c   Rigal, Olivier ^c   Tennevet, Isabelle ^c   Thery, Jean Christophe ^b,c   Alexandru, Cristina ^c   Guillemet, Cécile ^c   Moldovan, Cristian ^c   Veyret, Corinne ^c   Frebourg, Thierry ^a,b,c   Di Fiore, Frédéric ^a   Clatot, Florian ^b,c  

^a INSERM   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d Clinique du Cèdre   (France)

Author keywords

aromatase inhibitor resistance; circulating tumor DNA; digital PCR; ESR1 mutations; metastatic breast cancer

Indexed keywords

AROMATASE INHIBITOR; CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CODON; CRYOPRESERVATION; DISEASE COURSE; ESR1 GENE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MIDDLE AGED; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; BLOOD; BREAST NEOPLASMS; DRUG RESISTANCE; GENETICS; METASTASIS; MUTATION; PATHOLOGY; PROCEDURES; TUMOR EMBOLISM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MUTATION; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES;

EID: 84941885181     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29612     Document Type: Article

References (23)

1. Coleman RE, Bertelli G, Beaumont T, et al., UK guidance document: treatment of metastatic breast cancer. Clin Oncol R Coll Radiol G B 2012; 24: 169-76.
2. Cardoso F, Costa A, Norton L, et al., ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (abc2)†. Ann Oncol off J Eur Soc Med Oncol ESMO 2014; 25: 1871-88.
3. Mouridsen H, Gershanovich M, Sun Y, et al., Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer Group. J Clin Oncol off J Am Soc Clin Oncol 2001; 19: 2596-606.
4. Xu H-B, Liu Y-J, Li L,. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis. Clin Breast Cancer 2011; 11: 246-51.
5. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al., D538G mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 2013; 73: 6856-64.
6. Robinson DR, Wu Y-M, Vats P, et al., Activating esr1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013; 45: 1446-51.
7. Toy W, Shen Y, Won H, et al., ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013; 45: 1439-45.
8. Segal CV, Dowsett M,. Estrogen receptor mutations in breast cancer-new focus on an old target. Clin Cancer Res off J Am Assoc Cancer Res 2014; 20: 1724-6.
9. Jeselsohn R, Yelensky R, Buchwalter G, et al., Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res off J Am Assoc Cancer Res 2014; 20: 1757-67.
10. Li S, Shen D, Shao J, Crowder R, et al., Endocrine-therapy-resistant esr1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013; 4: 1116-30.
11. Oesterreich S, Davidson NE,. The search for esr1 mutations in breast cancer. Nat Genet 2013; 45: 1415-6.
12. Diaz LA, Bardelli A,. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol off J Am Soc Clin Oncol 2014; 32: 579-86.
13. Ignatiadis M, Dawson S-J,. Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol off J Eur Soc Med Oncol ESMO 2014; 25: 2304-13.
14. Bettegowda C, Sausen M, Leary RJ, et al., Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6: 224ra24.
15. El Messaoudi S, Rolet F, Mouliere F, et al., Circulating cell free DNA: preanalytical considerations. Clin Chim Acta Int J Clin Chem 2013; 424: 222-30.
16. Beutler E, Gelbart T, Kuhl W,. Interference of heparin with the polymerase chain reaction. BioTechniques 1990; 9: 166.
17. Dawson S-J, Tsui DWY, Murtaza M, et al., Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368: 1199-209.
18. Oxnard GR, Paweletz CP, Kuang Y, et al., Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res off J Am Assoc Cancer Res 2014; 20: 1698-705.
19. Qiu M, Wang J, Xu Y, et al., Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2015; 24: 206-12.
20. Madic J, Kiialainen A, Bidard F-C, et al., Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer 2015; 136: 2158-65.
21. Rothé F, Laes J-F, Lambrechts D, et al., Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol off J Eur Soc Med Oncol ESMO 2014; 25: 1959-65.
22. Yu M, Bardia A, Aceto N, et al., Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345: 216-20.
23. Rossi D, Khiabanian H, Spina V, et al., Clinical impact of small tp53 mutated subclones in chronic lymphocytic leukemia. Blood 2014; 23: 2139-47.